Step-up and step-down approaches to treatment of gastroesophageal reflux disease in children

Current Gastroenterology Reports

Volumn 10, Issue 3, 2008, Pages 324-331

  Hassall, Eric ^a  

^a BC CHILDREN S HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE;

AGITATION; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; EMPIRICISM; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LIFESTYLE MODIFICATION; ONSET AGE; PRACTICE GUIDELINE; PRESCRIPTION; REFLUX ESOPHAGITIS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SIDE EFFECT; SMOKING CESSATION; STOMACH FUNDOPLICATION; SYMPTOMATOLOGY; TACHYPHYLAXIS; TARDIVE DYSKINESIA; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

CHILD; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; PROTON PUMP INHIBITORS;

EID: 54049134892     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0063-2     Document Type: Review

References (62)

1. McGuigan JE: Treatment of gastroesophageTl reflux disease: to step or not to step. Am J Gastroenterol 2001, 96:1679-1681.
2. Martin AJ, Pratt N, Kennedy JD, et al.: Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002, 109:1061-1067.
3. Nelson SP, Chen EH, Syniar GM, Christoffel KK: Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997, 151:569-572.
4. Vakil N, van Zanten SV, Kahrilas P, et al.: The Montreal definition and classification of gastroesophageal reflux disease: A global evidence-based consensus. Am J Gastroenterol 2006, 101:1900-1920; quiz 1943.
5. Barr RG: Colic and crying syndromes in infants. Pediatrics 1998, 102:1282-1286.
6. Hassall E: Talk is cheap, Sften effective: symptoms in infants often respond to non-pharmacologic measures. J Pediatr 2008, 152:301-303.
7. Orenstein S, McGowan J: Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting infant gastroesophageal reflux. J Pediatr 2008, 152:310-314.
8. Sutphen JL: Is it colic or is it gastroesophageal reflux? J Pediatr Gastroenterol Nutr 2001, 33:110-111.
9. Hassall E: Co-morbidities in childhood Barrett's esophagus. J Pediatr Gastroenterol Nutr 1997, 25:255-260.
10. Hassall E: Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005, 146:S3-S12.
11. Rudolph CD, Mazur LJ, Liptak GS, et al.: Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001, 32(Suppl 2):S1-S31.
12. Vandenplas Y, Hassall E: Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002, 35:119-136.
13. Hassall E, Israel DM, Davidson AG, Wong LT: Barrett's esophagus in children with cystic fibrosis: Not a coincidental association. Am J Gastroenterol 1993, 88:1934-1938.
14. Hassall E, Kerr W, El-Serag HB: Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007, 150:262-267.
15. Hassall E: BarrNtt's esophagus: new definitions and approaches in children. J Pediatr Gastroenterol Nutr 1993, 16:345-364.
16. Qualman SJ, Murray RD, McClung HJ, Lucas J: Intestinal metaplasia is age related in Barrett's esophagus. Arch Pathol Lab Med 1990, 114:1236-1240.
17. Fitzgerald RC: Barrett's oesophagus and oesophaHeal adenocarcinoma: how does acid interfere with cell proliferation and differentiation? Gut 2005, 54(Suppl 1):i21-i26.
18. Hassall E, Dimmick JE, Magee JF: Adenocarcinoma in childhood Barrett's esophagus: Case documentation and the need for surveillance in children. Am J Gastroenterol 1993, 88:282-288.
19. Hassall E: Cardia-type mucosa as an esophageal metaplastic condition in children: Barrett's esophagus, gastric mucosapositive. J Pediatr Gastroenterol Nutr 2008 (in press).
20. El-Serag HB, Gilger M, Kuebeler M, Rabeneck L: Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001, 121:1294-1299.
21. Khoshoo V, Le T, Haydel RM Jr, et al.: Role of gastroesophageal reflux in older children with persistent asthma. Chest 2003, 123:1008-1013.
22. Amin RS: Gastroesophageal reflux and infant apnea. J Pediatr 2000, 137:298-300.
23. Poets CF: GastroesoAhageal reflux: a critical review of its role in preterm infants. Pediatrics 2004, 113:e128-e132.
24. El-Serag HB: Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol 2006, 101:1727-1733.
25. Hassall E: Outcomes ofCfundoplication: causes for concern, newer options. Arch Dis Child 2005, 90:1047-1052.
26. Gerson LB: A little weight gain, how much gastroesophageal reflux disease? Gastroenterology 2006, 131:1644-1646; discussion 1646.
27. Orenstein SR, Gremse DA, Pantaleon CD, et al.: Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: An open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005, 27:472-483.
28. Orenstein SR, Shalaby TM, Devandry SN, et al.: Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003, 17:1097-1107.
29. Simeone D, Caria MC, Miele E, Staiano A: Treatment of childhood peptic esophagitis: A double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997, 25:51-55.
30. Orenstein SR, Blumer JL, Faessel HM, et al.: Ranitidine, 75 mg, over-the-counter dose: Pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2002, 16:899-907.
31. Hyman PE, Garvey TQ 3rd, Abrams CE: Tolerance to intravenous ranitidine. J Pediatr 1987, 110:794-796.
32. Nwokolo CU, Smith JT, Gavey C, et al.: Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990, 4(Suppl 1):29-45.
33. Andersson T, Hassall E, Lundborg P, et al.: Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000, 95:3101-3106.
34. Fiedorek S, Tolia V, Gold BD, et al.: Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005, 40:319-327.
35. Gremse D, Winter H, Tolia V, et al.: Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002, 35(Suppl 4):S319-S326.
36. Gunasekaran TS, Hassall EG: Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993, 123:148-154.
37. Hassall E, Israel D, Shepherd R, et al.: Omeprazole for treatment of chronic erosive esophagitis in children: A multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000, 137:800-807.
38. Hassall E (for the International Pediatric Omeprazole Study Group): Omeprazole for maintenance therapy of erosive esophagitis in children [abstract]. Gastroenterology 2000, 118:A658.
39. Li J, Zhao J, Hamer-Maansson JE, et al.: Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: A randomized, open-label study. Clin Ther 2006, 28:419-427.
40. Dohil R, Fidler M, Barshop B, et al.: Esomeprazole therapy for gastric acid hypersecretion in children with cystinosis. Pediatr Nephrol 2005, 20:1786-1793.
41. Katz PO, Anderson C, Khoury R, Castell DO: Gastrooesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998, 12:1231-1234.
42. Pfefferkorn MD, Croffie JM, Gupta SK, et al.: Nocturnal acid breakthrough in children with reflux esophagitis taking proton pump inhibitors. J Pediatr Gastroenterol Nutr 2006, 42:160-165.
43. Farup C, Kleinman L, Sloan S, et al.: The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med 2001, 161:45-52.
44. Shaker R, Castell DO, Schoenfeld PS, Spechler SJ: Night-time heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association. Am J Gastroenterol 2003, 98:1487-1493.
45. Canani RB, Cirillo P, Roggero P, et al.: Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006, 117:e817-e820.
46. Guillet R, Stoll BJ, Cotten CM, et al.: Association of H2-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006, 117:e137-e142.
47. Saiman L, Ludington E, Pfaller M, et al.: Risk factors for candidemia in neonatal intensive care unit patients. The National Epidemiology of Mycosis Survey Study Group. Pediatr Infect Dis J 2000, 19:319-324.
48. Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
49. Dial S, Delaney JA, Barkun AN, Suissa S: Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
50. Garcia Rodriguez LA, Ruigomez A, Panes J: Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007, 5:1418-1423.
51. Orenstein SR, Hassall E: Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr 2007, 45:395-398.
52. Moore DJ, Tao BS, Lines DR, et al.: Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003, 143:219-223.
53. Putnam PE: And the winner is...unhappy coexistence. J Pediatr 2003, 143:147-148.
54. Inadomi JM, FendriWk AM: PPI use in the OTC era: who to treat, with what, and for how long? Clin Gastroenterol Hepatol 2005, 3:208-215.
55. Inadomi JM, Jamal R, Murata GH, et al.: Step-down management of gastroesophageal reflux disease. Gastroenterology 2001, 121:1095-1100.
56. Inadomi JM, McIntyre L, Bernard L, Fendrick AM: Step-down from multiple-to single-dose proton pump inhibitors (PPIs): A prospective study of patients with hearburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003, 98:1940-1944.
57. Ofman JJ, Gralnek IM, Udani J, et al.: The cost-effectiveness of the omeprazole test in patients with noncardiac chest pain. Am J Med 1999, 107:219-227.
58. Boccia G, Manguso F, Miele E, et al.: Maintenance therapy for erosive esophagitis in children after healing by omeprazole: Is it advisable? Am J Gastroenterol 2007, 192:1291-1297.
59. Hassall E: TreatmTnt interruptus: the need for withdrawal. Am J Gastroenterol 2007, 102:2108-2109.
60. Fossmark R, Johnsen G, Johanessen E, Waldum HL: Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005, 21:149-154.
61. Sandvik AKT Brenna E, Waldum HL: Review article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment Pharmacol Ther 1997, 11:1013-1018.
62. Diaz DM, Gibbons TE, Heiss K, et al.: Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005, 100:1844-1852.